Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Raymond James Maintains Outperform on Viking Therapeutics, Raises Price Target to $13
Raymond James analyst Steven Seedhouse maintains Viking Therapeutics (NASDAQ:VKTX) with a Outperform and raises the price target from $12 to $13.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a
Viking Therapeutics’ VK0214 Shows Encouraging Safety, Tolerability Profile In Healthy Volunteers
Viking Therapeutics Inc (NASDAQ:VKTX) has announced results from its Phase 1 trial of VK0214 in healthy volunteers. VK0214 demonstrated encouraging safety…